| 2.13 -0.13 (-5.75%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.79 | 1-year : | 3.26 |
| Resists | First : | 2.39 | Second : | 2.79 |
| Pivot price | 2.1  |
|||
| Supports | First : | 1.95 | Second : | 1.68 |
| MAs | MA(5) : | 2.25 |
MA(20) : | 2.04 |
| MA(100) : | 1.78 |
MA(250) : | 1.76 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 74.5 |
D(3) : | 83.9 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 3.53 | Low : | 0.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRBU ] has closed below upper band by 45.7%. Bollinger Bands are 60.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.27 - 2.29 | 2.29 - 2.3 |
| Low: | 2.08 - 2.09 | 2.09 - 2.11 |
| Close: | 2.11 - 2.13 | 2.13 - 2.15 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Fri, 24 Apr 2026
Caribou Biosciences (NASDAQ: CRBU) sets 2026 director, auditor and charter votes - Stock Titan
Tue, 21 Apr 2026
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year? - qz.com
Tue, 31 Mar 2026
Caribou rises on FDA RMAT designation (CRBU:NASDAQ) - Seeking Alpha
Tue, 31 Mar 2026
FDA gives advanced therapy status to Caribou's myeloma CAR-T - Stock Titan
Thu, 05 Mar 2026
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 37.6 (%) |
| Shares Short | 6,470 (K) |
| Shares Short P.Month | 7,230 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.27 |
| Profit Margin | 0 % |
| Operating Margin | -722 % |
| Return on Assets (ttm) | -34.3 % |
| Return on Equity (ttm) | -79 % |
| Qtrly Rev. Growth | 89.6 % |
| Gross Profit (p.s.) | -1 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -1.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -1.34 |
| PEG Ratio | 0 |
| Price to Book value | 1.66 |
| Price to Sales | 18.44 |
| Price to Cash Flow | -1.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|